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ABSTRACT
Background Agalsidase β is a form of enzyme
replacement therapy for Fabry disease, a genetic disorder
characterised by low α-galactosidase A activity,
accumulation of glycosphingolipids and life-threatening
cardiovascular, renal and cerebrovascular events. In
clinical trials, agalsidase β cleared glycolipid deposits
from endothelial cells within 6 months; clearance from
other cell types required sustained treatment. We
hypothesised that there might be a ‘lag time’ to clinical
benefit after initiating agalsidase β treatment, and
analysed the incidence of severe clinical events over time
in patients receiving agalsidase β.
Methods The incidence of severe clinical events (renal
failure, cardiac events, stroke, death) was studied in
1044 adult patients (641 men, 403 women) enrolled in
the Fabry Registry who received agalsidase β (average
dose 1 mg/kg every 2 weeks) for up to 5 years.
Results The incidence of all severe clinical events was
111 per 1000 person-years (95% CI 84 to 145) during
the first 6 months. After 6 months, the incidence
decreased and remained stable within the range of
40–58 events per 1000 patient-years. The largest
decrease in incidence rates was among male patients
and those aged ≥40 years when agalsidase β was
initiated.
Conclusions Contrary to the expected increased
incidence of severe clinical events with time, adult
patients with Fabry disease had decreased incidence of
severe clinical events after 6 months treatment with
agalsidase β 1 mg/kg every 2 weeks.
Trial registration number NCT00196742.
INTRODUCTION
Fabry disease (OMIM #301500) is a rare, X
linked, multisystemic, multiorgan disorder in which
globotriaosylceramide (GL-3) and other glyco-
sphingolipids accumulate within lysosomes due to
deficient activity of α-galactosidase A (α-GalA).1 2
The progressive accumulation of GL-3 in multiple
cell types is ultimately associated with severe,
potentially life-threatening target-organ complica-
tions,3 including cardiac events,4 stroke,5 renal
failure6 and premature death.7 8
The spectrum of clinical presentations is wide
and includes the severe classic male phenotype,
later-onset variant phenotypes and variable clinical
presentations in female patients ranging from
asymptomatic to, occasionally, a severe classic
phenotype.1 2 9
Since 2001, enzyme replacement therapy (ERT)
has been available for treating patients with Fabry
disease.10 11 Agalsidase β (Fabrazyme; Genzyme, a
Sanofi company, Cambridge, Massachusetts, USA),
a form of recombinant human α-GalA, is approved
for use as ERT in Fabry disease in the USA, Europe
and many other countries throughout the world.
Clinical trials of agalsidase β at dose 1 mg/kg every
2 weeks have shown that treatment results in the
complete clearance of GL-3 deposits in the vascular
endothelial cells of the kidneys, heart and skin at
6 months in the majority of adult patients, thereby
reducing the overall glycolipid burden,10 12
although minimal clearance was observed in cardio-
myocytes and podocytes.12 13
Due to the relatively recent availability of ERT, and
the commonly occurring delays in diagnosis,14 15
ERT has been initiated in many patients after substan-
tial target organ damage has occurred. Not unexpect-
edly, therefore, serious Fabry disease-related clinical
events have occurred in these patients despite ERT16–
18 and the use of ERT for patients with advanced
kidney disease has been questioned.19 The key ques-
tion, however, is not if ERT completely prevents
severe clinical events in patients with Fabry disease,
but whether ERT reduces the incidence and/or pro-
gression of severe clinical events. Given the difficulty
and ethical concerns of conducting long-term
placebo-controlled clinical trials in patients with
Fabry disease, patient registry data are needed to gain
insights into the effect of ERTon the incidence rates
of severe clinical events.
In this study, we analysed data from adult patients
with Fabry disease enrolled in the Fabry Registry
(ClinicalTrials.gov identifier: NCT00196742) with
the objective of determining trends in the incidence
of severe, potentially life-threatening clinical events
over time in patients receiving up to 5 years treatment
with agalsidase β, at a dose of 1 mg/kg every 2 weeks.
The analysis was limited to adult patients, as severe
clinical events are relatively uncommon in childhood
due to the relatively slow disease progression observed
in the majority of patients with Fabry disease.
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METHODS
Study design
The Fabry Registry was initiated in 2001 as part of an initiative
to help healthcare professionals involved in the treatment or
diagnosis of Fabry disease better understand the disease and its
management, and to help create treatment monitoring guide-
lines for the disease. Patient participation in the Fabry Registry
is voluntary and the total number of patients with Fabry disease
who will participate in the Fabry Registry and the associated
person-years of follow-up are not predefined. It is at the discre-
tion of the treating physician to determine the testing protocol
for each patient.
Inclusion/exclusion criteria
To be included in these analyses, Fabry Registry adult patients
must have received agalsidase β as their initial source of ERT
given at or near the recommended licensed dose of 1 mg/kg
every 2 weeks (average dose range: ≥0.9 to <1.1 mg/kg every
2 weeks) for up to 5 years. Adult patients aged ≥18 years at
ERT initiation were eligible for this analysis. Patients who devel-
oped end stage renal failure (signified by dialysis or transplant)
before starting agalsidase β were excluded because they have
already had an irreversible organ failure. Fabry Registry patients
with other pretreatment clinical events were included in our
analysis. Patients with non-classic, later-onset variant mutations
(p.Asn215Ser (N215S), p.Arg112His (R112H), p.Ala97Val
(A97V), p.Gly35Arg (G35R), p.Ile317Thr (I317T),
p.Arg301Gln (R301Q); n=56),20–25 as reported in the ‘fabry-
database.org’ Fabry mutation database,26 27 were excluded from
the analysis. The ‘fabry-database.org’ database of clinical pheno-
types, genotypes and structures of mutant GLAs has been built
by the research group led by Dr H Sakuraba in order to help
researchers and clinicians who study Fabry disease. The database
currently contains more than 640 different mutations.27
Moreover, individuals with non-pathogenic Fabry gene poly-
morphisms (p.Asp313Tyr (D313Y), p.Arg118Cys (R118C);
n=3)28–30 were excluded. No patients in the cohort had a p.
Ala143Thr or IVS4+919G>A mutation, or the polymorphism
p.Glu66Gln (E66Q). The analysis population included: (1)
patients with mutations categorised in the ‘fabry-database.org’
Fabry mutation database as being associated with ‘classic’ Fabry
disease; (2) patients with mutations not entered or classified in
this database; (3) patients for whom mutations were not
reported in the Fabry Registry.
Outcomes and follow-up
Death due to any cause, and the following three severe (poten-
tially life-threatening) clinical event categories were included in
the analysis: (A) renal events: chronic dialysis (>40 days) or
renal transplantation; (B) cardiovascular events: myocardial
infarction, first-time congestive heart failure, atrial fibrillation,
ventricular tachycardia, evidence of progressive heart disease
sufficiently severe to require a pacemaker, heart bypass surgery,
coronary artery dilatation or implantation of a cardioverter/
defibrillator; and (C) cerebrovascular events: haemorrhagic or
ischaemic stroke. The outcome was defined as the time to death
or the first event in any of the above predefined categories.
Exposure time started when each patient began agalsidase β
treatment, and ended at the time of their first reported severe
clinical event after starting ERT, when they stopped receiving
agalsidase β (due to treatment interruption or switch to another
source of ERT), or at the last follow-up visit. Follow-up data
were not included beyond 25 June 2009 because many patients
began temporary agalsidase β dose-reductions due to an inter-
ruption in the manufacturing process and a subsequent global
shortage of agalsidase β around this time. Follow-up time was
censored at 5 years on agalsidase β treatment because in 2009
relatively few patients had been on ERT for longer than 5 years.
Statistical methods
Descriptive statistics were used to summarise the demographic
and medical characteristics of patients at the time of agalsidase β
initiation. Continuous variables were compared using the
Wilcoxon test and categorical variables were compared using
the χ2 or Fisher’s exact test, when appropriate. For the inci-
dence rate tables, the rate for the first event per 1000 patient-
years of follow-up time and the associated 95% CIs were com-
puted for each time period on treatment.31 Total patient-years
of follow-up time was calculated as the sum of follow-up times
for each patient within each specified category. Incidence rates
were calculated for all patients and further stratified by: (A) non-
renal event prior to first agalsidase β infusion (‘pre-ERT event’);
(B) median age at initiation of agalsidase β treatment; and (C)
gender. Finally, Cox proportional hazards regression models
were used to evaluate the impact of risk factors associated with
severe clinical events, including a severe non-renal event prior
to first ERT, age at agalsidase β initiation and gender. The small
number of excluded individuals with Fabry gene polymorphisms
or later-onset variant mutations did not allow for a meaningful
separate analysis of these groups to assess time to treatment
benefit in these groups. Statistical analyses were performed
using SAS statistical software V.9.2 (SAS Institute, Cary, North
Carolina, USA). An α level of 0.05 was used as the criterion for
statistical significance.
RESULTS
Patient disposition
As of 25 June 2009, 1044 adults with Fabry disease (641 men,
403 women) treated for up to 5 years with agalsidase β (average
dose range: ≥0.9 to <1.1 mg/kg every 2 weeks) were included
in the present analysis. Mean (SD) time on agalsidase β was 2.8
(1.8) years with a maximum follow-up of 5 years. The median
age at which agalsidase β was initiated was 40 years (IQR: 31–
50 years) and it was used for further subgroup analysis.
Baseline patient demographics
The baseline characteristics at the time of initiation of agalsidase
β treatment are shown in table 1. Many patients had advanced
disease with a frequency of pre-ERT events of 17% , left ven-
tricular hypertrophy (LVH) 61%, and an estimated glomerular
filtration rate (eGFR) <60 mL/min/1.73 m2 of 24%.
Furthermore, patients who started agalsidase β treatment at age
≥40 years had more evidence of renal and cardiac organ
damage compared with patients who started treatment at age
<40 years (table 1). In patients who started ERT at age
≥40 years, the proportion of patients with eGFR <60 mL/min/
1.73 m2 was 33% compared with 15% of those who initiated
ERTat age <40 years. Similarly, more patients who started treat-
ment at age ≥40 years had a baseline urine protein:creatine ratio
of >0.5 g/g (54% vs 38%), LVH (79% vs 37%), arrhythmias
(30% vs 17%), systolic blood pressure >130 mm Hg (47% vs
35%) and diastolic blood pressure >80 mm Hg (46% vs 30%)
compared with those who started ERT at age <40 years.
Missense (42%) and nonsense mutations (14%) were most com-
monly reported, followed by frameshift mutations (10%).
Genotype data were not available for 27% of the patients (see
online supplementary table S1). Four hundred patients had
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mutations categorised in the ‘fabry-database.org’ database as
being associated with classic Fabry disease, whereas 365 patients
had mutations not entered or classified in this database.27
Type and timing of first severe clinical events following
initiation of ERT
Overall, 177 of 1044 (17%) patients had a severe clinical event
within 5 years of agalsidase β treatment initiation: 120 events
occurred in 641 male patients (19%) and 57 events occurred in
403 women (14%). For all patients, cardiac and renal events
were the most common, followed by strokes and death. The
absolute number of events, defined by clinical category over
time following initiation of ERT for men and women are shown
in online supplementary figure S1. In 54 of 177 (31%) patients
with severe clinical events, the first event occurred during the
first 6 months of ERT. The pattern of first event occurrence
appeared similar across individual event types, except for death
which was uncommon throughout the maximum follow-up
interval. The event subtypes together with the overall frequen-
cies of occurrence are shown in the online supplementary table
S2. Of the cardiovascular events, ventricular tachycardia (2%)
contributed the least to the first event in the composite (other
cardiovascular events: myocardial infarction 7%, first-time con-
gestive heart failure 6%, atrial fibrillation 8%, evidence of pro-
gressive heart disease sufficiently severe to require a cardiac
procedure 16%).
Incidence of combined severe clinical events over time
following initiation of ERT
Clinical events were combined when calculating incidence rates,
as there were too few events to analyse incidence rates for indi-
vidual categories (cardiac, stroke, renal and death). The
incidence rate was 111 events per 1000 patient-years (95% CI
84 to 145) during the first 6 months, followed by decreased
incidence rates with longer exposure to agalsidase β (figure 1).
After 6 months of ERT, the incidence rate for severe clinical
events decreased and remained stable within the range of 40–58
Figure 1 Incidence rate of severe clinical events (rate per 1000
patient-years with 95% CIs) over time following initiation of enzyme
replacement therapy.
Table 1 Baseline characteristics of adult patients with Fabry disease receiving agalsidase β (1 mg/kg every 2 weeks) as their initial source of
ERT and included in the study
Characteristic
All patients
(n=1044)
Age <40 years at
first treatment
(n=526)
Age ≥40 years at
first treatment
(n=518)
p Value
(comparing age groups)
Men, n (%) 641 (61) 390 (74) 251 (49) <0.01
Severe clinical event pre-ERT,* n (%) 172 (17) 35 (7) 137 (26) <0.01
Renal factors
eGFR,† n 695 349 346
Mean±SD (mL/min/1.73 m2) 85±34 100±33 70±27 <0.01
<60 mL/min/1.73 m2, n (%) 166 (24) 51 (15) 115 (33) <0.01
Protein:creatine ratio, n 461 227 234
>0.5 g/g, n (%) 213 (46) 87 (38) 126 (54) <0.01
Cardiac factors
Echocardiography (pre-ERT), n 667 293 374
LVH (pre-ERT),†‡ n (%) 406 (61) 109 (37) 297 (79) <0.01
Arrhythmia (pre-ERT),§ n (%) 247 (24) 90 (17) 157 (30) <0.01
Systolic blood pressure,† n 727 365 362
Mean±SD (mm Hg) 125±16 123±15 127±17 <0.01
≥130 mm Hg, n (%) 297 (41) 127 (35) 170 (47) <0.01
Diastolic blood pressure,† n 727 365 362
Mean±SD (mm Hg) 75±11 73±11 77±11 <0.01
≥80 mm Hg, n (%) 274 (38) 109 (30) 165 (46) <0.01
*Non-renal event (stroke or cardiac event).
†Baseline eGFR values and blood pressure values were measured −3/+3 months of first ERT, and wall thickness values were measured within 3 months of the first ERT.
‡LVH criterion was wall thickness ≥12 mm. The frequency of occurrence of LVH was determined using available left posterior wall thickness values in the range 5–35 mm and/or a ‘yes’
response to the checkbox question ‘LVH present?’.
§Arrhythmia was based on the treating physician’s judgement and indicated by a ‘yes’ or ‘no’ response.
eGFR, estimated glomerular filtration rate; ERT, enzyme replacement therapy; LVH, left ventricular hypertrophy.
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events per 1000 patient-years for the rest of the follow-up
interval.
Incidence of combined clinical events by history of pre-ERT
event, age and gender
Given that Fabry disease is clinically diverse, incidence rates of
clinical events were stratified by history of pre-ERT clinical
event, median age at agalsidase β initiation and gender (table 2).
The number of years on ERTwas presented in three categories:
0–0.5 year, >0.5–1 year and >1–5 years. There was attenuation
of the incidence rates of severe clinical events after the first
6 months of ERT. Differences between strata were more pro-
nounced among patients with high risk of events (ie, age
≥40 years when ERT was started or male sex) during the first
6 months of ERT (table 2).
Among patients with a pre-ERT event, the incidence rate
during the first 6 months was 166 clinical events per 1000
patient-years (95% CI 88 to 283). The clinical event rate
decreased after 6 months to 102 per 1000 patient-years (95%
CI 41 to 210) during the 0.5–1 year period and remained at
102 per 1000 patient-years (95% CI 68 to 146) during the >1–
5 years period. Among patients aged ≥40 years at ERT initi-
ation, the incidence of clinical events during the first 6 months
was 177 events per 1000 patient-years (95% CI 128 to 239),
which decreased to 74 per 1000 patient-years (95% CI 42 to
123) during the >0.5–1 year period and 79 per 1000 patient-
years (95% CI 61 to 99) during the >1–5 years period. Among
men, the incidence rate during the first 6 months was 124 per
1000 patient-years (95% CI 87 to 171), which decreased after
this time period to 49 per 1000 patient-years (95% CI 26 to
85) during the >0.5–1 year period and 54 per 1000 patient-
years (95% CI 42 to 68) during the >1–5 years period. There
were too few clinical events to meaningfully analyse the patient
subgroups based on disease severity.
Risk factors for severe clinical events
The results of the Cox proportional hazards regression analysis
assessing the association of risk factors with clinical events are
shown in table 3. Among patients with pre-ERT clinical events,
the risk of developing an event after starting agalsidase β was
not significantly different during 0–0.5 year compared with
those who had no previous clinical events (Model 1: HR 1.1,
Table 2 Incidence rates of severe clinical events (renal event, cardiac event, stroke or death) per 1000 patient years while on agalsidase β by
history of pre-ERT event, age and sex (177 severe clinical events were observed during 5 years maximal follow-up)
Years on agalsidase β
0–0.5 year >0.5–1 year >1–5 years
Pre-ERT event: yes (n=172)
Severe events, n 13 7 29
Incidence rate*(95% CI) 166 (88 to 283) 102 (41 to 210) 102 (68 to 146)
Pre-ERT event: no (n=872)
Severe events, n 41 13 74
Incidence rate*(95% CI) 101 (72 to 137) 37 (19 to 62) 44 (34 to 55)
Age ≥40 years at first ERT (n=518)
Severe events, n 42 15 69
Incidence rate*(95% CI) 177 (128 to 239) 74 (42 to 123) 79 (61 to 99)
Age <40 years at first ERT (n=526)
Severe events, n 12 5 34
Incidence rate*(95% CI) 48 (25 to 85) 22 (7 to 52) 31 (22 to 43)
Men (n=641)
Severe events, n 37 13 70
Incidence rate*(95% CI) 124 (87 to 171) 49 (26 to 85) 54 (42 to 68)
Women (n=403)
Severe events, n 17 7 33
Incidence rate*(95% CI) 91 (53 to 145) 43 (17 to 88) 49 (34 to 68)
*Per 1000 patient-years.
ERT, enzyme replacement therapy.
Table 3 Cox proportional hazards regression analysis assessing the time dependence of risk factors for clinical events*
Years on agalsidase β
Model 1: 0–0.5 year Model 2: >0.5–5 years Model 3: >0–5 years
HR 95% CI p Value HR 95% CI p Value HR 95% CI p Value
Pre-ERT event: yes (vs no) 1.1 0.6 to 2.0 0.81 1.8 1.2 to 2.7 <0.01 1.5 1.1 to 2.1 0.02
Age ≥40 years at first ERT (vs age <40 years) 4.4 2.2 to 8.7 <0.01 2.5 1.7 to 3.8 <0.01 2.9 2.1 to 4.2 <0.01
Male (vs female) 1.9 1.1 to 3.4 0.03 1.5 1.0 to 2.1 0.06 1.6 1.1 to 2.2 <0.01
*Three models were run to assess if the incidence of events according to the above factors was time-dependent: Model 1 examined risk factors within the first 6 months; Model 2
examined risk factors within 6 months to 5 years; and Model 3 examined risk factors for the entire analysis period of up to 5 years.
ERT, enzyme replacement therapy.
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95% CI 0.6 to 2.0, p=0.81), but increased thereafter (Model 2:
HR 1.8, 95% CI 1.2 to 2.7, p<0.01) (table 3). Compared with
patients aged <40 years at first ERT, patients aged ≥40 years at
first ERT had a significantly higher risk of having an event
during 0–0.5 year (Model 1: HR 4.4, 95% CI 2.2 to 8.7,
p<0.01), but this decreased during the period >0.5–5 years
(Model 2: HR 2.5, 95% CI 1.7 to 3.8, p<0.01). Compared
with female patients, the risk of a clinical event in male patients
was significantly higher during 0–0.5 year (Model 1: HR 1.9,
95% CI 1.1 to 3.4, p=0.03), but not thereafter (Model 2: HR
1.5, 95% CI 1.0 to 2.1, p=0.06). There was no evidence of a
violation in the proportional hazards assumption with the
number of events available for this analysis.
DISCUSSION
Severe clinical events are hard end points that may provide
stronger evidence of clinical benefit with agalsidase β than surro-
gate end points such as clearance of GL-3 deposits, degree of
LVH or changes in renal function (eg, eGFR). Our analysis of
Fabry Registry data provides new information on the incidence
of severe clinical events over time for adult patients treated with
agalsidase β. We show that the incidence rate for severe clinical
events decreases after the first 6 months of treatment with agal-
sidase β. Those patients at highest risk for severe clinical events,
due to older age or male sex, displayed the greatest absolute
reduction in event rate over time on agalsidase β, and in particu-
lar had the greatest reduction in the incidence rates for severe
clinical events after the first 6 months of treatment. These
results are notable because the occurrence of severe clinical
events, despite ERT, has recently been emphasised16 17 and the
efficacy of ERT for patients with more Fabry-related kidney
involvement has been questioned.19
Our observation of a decrease in severe events over time is
consistent with findings from a phase IV trial in which 82 adults
with advanced Fabry disease were randomised to either agalsi-
dase β 1 mg/kg every 2 weeks (mean age 47 years) or placebo
(mean age 44 years).32 After a median follow-up period of
18 months, the incidence of a first severe clinical event was
reduced for patients treated with agalsidase β compared with
those in the placebo group (HR 0.47, 95% CI 0.21 to 1.03).32
Together these data support the hypothesis that treatment with
agalsidase β reduces the rate of severe clinical events, rather
than the alternative potential explanation that ERT causes an
absolute increase in the short-term incidence of severe clinical
events. In this regard, a single-centre study of 57 ERT-treated
patients observed that, in comparison to a historical group of
untreated patients, the odds for development of a first severe
clinical event declined with longer treatment duration per year
of ERT (OR 0.81, 95% CI 0.68 to 0.96).17
In the general population, ageing is a known risk factor for
the development of cardiac, renal and stroke events and a prior
cardiac or stroke event is associated with a higher risk of a
second cardiac or stroke event.33 34 In patients with Fabry
disease, the natural course of the disease is also associated with
an increasing number of these events as the severity of organ
involvement increases as patients age with cardiac disease being
the leading cause of death.7 8 Thus, the observed decrease in
the incidence rate of severe clinical events during the first 5
years of agalsidase β treatment is important and consistent with
a modifying effect of ERT on the course of Fabry disease in
adults.
In the present cohort, the occurrence of a severe clinical
event prior to the initiation of agalsidase β was associated with a
higher risk of experiencing another serious event while receiving
treatment after the first 6 months of treatment. This finding was
observed even though we excluded patients who had a severe
renal event leading to organ failure (dialysis or transplantation)
prior to starting ERT. Recent studies have emphasised the asso-
ciated risks for mortality, stroke and coronary heart disease asso-
ciated with albuminuria and eGFR <60 mL/min/1.73 m2 in the
general population.35–37 These same risk factors are also evident
in the baseline characteristics of patients with Fabry disease
described in this report. However, patients who had a severe
clinical event prior to ERT initiation may have subsequently
been given appropriate adjunctive therapy, which may result in a
lower estimation of the subsequent event rates in this group.
In the current analysis, many patients started agalsidase β rela-
tively late in the course of their disease, which reflects the delay
in diagnosis of Fabry disease and the availability of ERT.14 15
Indeed, the baseline characteristics of the patients included in
our study demonstrate a higher prevalence of advanced disease
in those aged ≥40 years before ERT initiation. Data from a pre-
vious Fabry Registry study showed that 81% of 52 patients with
classic Fabry disease, who originally participated in a rando-
mised phase III clinical trial, did not experience any severe clin-
ical events during a median 10-year period of agalsidase β
treatment.38 Several studies have also shown that patients who
initiate treatment at a younger age, and with less kidney involve-
ment, benefit the most from therapy in terms of changes in
white matter lesions, left ventricular mass and surrogate out-
comes such as decline in eGFR.38–41
Delayed time between an intervention and the time at which
improved health outcomes/clinical benefits are seen leads to ‘lag
time’ bias, and if this effect is not considered when results are
analysed, there may be inappropriate pessimism with cost-
effectiveness analyses of the benefits of new therapies.42 The
results from our analysis are consistent with a delay or lag time
of 6 months from initiation to clinical benefit from agalsidase β.
There are several recent examples of delayed time to benefit
varying from 6 months for statin therapy in secondary preven-
tion of cardiovascular effects, to >10 years in prostate cancer
screening or intensive insulin therapy.43–46 For example, the
Diabetes Control and Complications Trial/Epidemiology of
Diabetes Interventions and Complications study in diabetic
kidney disease recently published results with a median
follow-up of 22 years.44 It was shown that intensive insulin
therapy was associated with a lower long-term risk of an
impaired eGFR, but that the curves only began to differ after a
decade of follow-up.44
For Fabry disease, we can only speculate as to the patho-
physiological effects underlying the observed decreased inci-
dence of severe events during treatment with agalsidase β. A
placebo-controlled randomised clinical trial reported that 70%
of patients treated with 1 mg/kg agalsidase β have nearly com-
plete clearance of kidney microvascular endothelial glycolipid
deposits after 6 months.10 12 Thus, the lag time to benefit
observed in our analysis is consistent with the time course of
GL-3 clearance from vascular endothelial cells. Although GL-3
clearance of additional cell types, such as podocytes and cardio-
myocytes, takes longer than 6 months,12 47 48 clearance of vas-
cular endothelial cells may be significant in terms of endothelial
cell biology and as a marker of overall glycolipid burden. Thus,
we speculate that the lag time to benefit depends on significant
glycolipid clearance from endothelial cells and the associated
subsequent reversal of endothelial cell dysfunction.
The patient population in our study is representative of adult
patients receiving ERT with respect to age, gender18 41 and
genotype (see online supplementary tables S1 and S3).
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Considering that the patient population is representative of
patients with Fabry disease in the clinic, the findings of the
current analysis may inform therapeutic decision-making in
these patients. While our findings emphasise the importance of
starting ERT at a relatively young age, we also clearly demon-
strate a benefit of ERT in older patients with Fabry disease with
more advanced disease who better represent the majority of
patients reported to date.19 49
Fabry disease is a clinically heterogeneous disease and little is
known about the natural progression of Fabry disease in patients
with later-onset variant mutations and reference studies in which
ERT-treated patients with these mutations and classically affected
patients have been analysed separately are lacking. Therefore, the
main analysis population was restricted to patients with muta-
tions categorised as being associated with classic Fabry disease,
patients with mutations not entered or classified in the ‘fabry-
database.org’ database,27 and patients for whom mutations were
not reported in the Fabry Registry (27% of the patients); even
though these mutations were not recorded in the Fabry registry,
the treating physicians classified these patients as ‘classical’ Fabry
disease. The frequencies of severe events in the latter two groups
of patients (117 events in 644 patients (18%)) and in patients
with mutations associated with classic Fabry disease (60 events in
400 patients (15%)) were comparable (see online supplementary
table S3). Most patients have a positive family history (data not
shown), and all received ERT suggesting that disease severity cri-
teria for treatment initiation, as per published general guidelines
or local/national protocols, had been met. Taken together, the
results support the inclusion of patients with unclassified or
missing mutations. While the percentage of patients with avail-
able mutation data included in the current analysis is relatively
high (73%), a priority of the Registry is to increase the amount of
mutation data entered.
Several other limitations and cautions need to be considered
when interpreting the results. The Fabry Registry is not a clinical
trial and interpretation of these findings is limited by the lack of
an appropriate parallel-untreated control group due to the
absence of a well-matched contemporaneous group of patients.
Patient participation in the Fabry Registry is voluntary and not
all patients with Fabry disease have been identified; also, not all
patients will wish to participate. A limitation of any registry
includes a possible patient selection bias toward the inclusion of
more severely affected treatment-naïve or treated patients. In
addition, event surveillance may be more comprehensive imme-
diately following institution of ERT, which could explain in part
the results reported herein. Substantially more men than women
are included in this study; thus, the results for female patients
apply primarily to women with manifestations of Fabry disease
that were severe enough to have been treated with ERT.
Furthermore, although the Fabry Registry provides a recom-
mended schedule of assessments, patients and their treating phy-
sicians ultimately determine the timing of assessments and the
time intervals at which they are carried out. Local standards of
care may differ between treatment sites and across all time
points, especially with respect to the use of vasculoprotective
and renoprotective adjunctive therapies. Thus, clinical data may
be incomplete for some patients and some assessments or events
may be under-reported; additionally, some patients may be lost
to follow-up. The absolute event rates are low overall, so that
caution is warranted in interpreting the event rate in any indi-
vidual short interval, as the CIs for the incidence rates are
increased for short follow-up intervals.
Serum-mediated inhibition of ERTs is emerging as an import-
ant issue particularly in male patients with classic Fabry
disease.50 No systematic evaluation of this issue was available
for inclusion in the manuscript. Incompleteness of the data set
for the temporary dose reduction period precluded a meaning-
ful analysis of clinical events occurring after dose reductions.
The focus of the current analyses was: (A) first severe clinical
event in order to understand primary prevention associated
with agalsidase β treatment; (B) a time frame of up to 5 years
on agalsidase β, as the number of patients treated for longer
than 5 years was very low; and (C) patients treated with the
approved dose and formulation of agalsidase β. Further research
is needed to understand outcomes for longer periods of time or
other doses/formulations of ERT. A major strength of this ana-
lysis is that it represents the largest longitudinal follow-up data
set and evaluation of time-to-event analysis for severe clinical
events in adult patients with Fabry disease treated with agalsi-
dase β.
In conclusion, the occurrence of severe clinical events in
patients with Fabry disease decreases after the first 6 months of
initiation of treatment with agalsidase β. This is in contrast to
the expected increase in events due to ageing. Interestingly, the
decrease in the incidence of severe clinical events with time on
agalsidase β was most conspicuous for those populations at
greater risk of events because of older age or male gender.
These observations are also consistent with a delayed benefit
after initiation of agalsidase β in patients with Fabry disease,
which is similar to the time needed to clear vascular endothelial
cells of GL-3 deposits with ERT. Although the small number of
events precluded further subgroup analysis, older age
(≥40 years) at initiation of treatment was associated with more
advanced disease. The apparent clinical benefit of ERT for
serious clinical events was observed even in patients with more
advanced disease, supporting prior clinical trial results32 and
providing an alternative perspective to recent recommendations
for withholding ERT in patients with more advanced disease.19
Time-to-event analysis will be important in future studies that
compare different doses or preparations of ERT, or other
modalities for treating Fabry disease.49
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